Schueller, J.; Mueller, T.
Here, we provide detailed information on an inhalation study performed with Nrf2-/- mice and their corresponding wild-type littermates exposed to mainstream smoke from the Kentucky reference cigarette 2R4F. The information is supplementary to that in Thomas Müller’s presentation “from cellular genotype to cigarette-smoke-induced phenotype: the case of Nrf2”. Mice were exposed to 750 µg total particulate matter/l for 2, 3, or 4 hours per day (low, medium, and high dose groups) for 5 days per week over 5 months, with a post-exposure period of 13 days for the medium dose group. As key endpoints (in addition to the transcriptomics data presented by Thomas Müller), we analyzed the histopathology; inflammatory cells in lung tissue; inflammatory cells, cytokines, and chemokines in bronchoalveolar lavage fluid; detection of lung tissue destruction using morphometry, and functional respiratory changes using forced pulmonary maneuvers. Additional exploratory endpoints were the determination of activation markers on alveolar macrophages, the sub-typing of lymphocytes in bronchoalveolar lavage fluid, and the alteration of gene expression in the lungs. The results underline the relevance of Nrf2 activation as a general defense mechanism against CS-induced cellular stress. Their quantitative dimension will be discussed in the context of published data.
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.